Designing multi-target drugs
"Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs...
Saved in:
| Other Authors | , |
|---|---|
| Format | Electronic eBook |
| Language | English |
| Published |
Cambridge, U.K. :
RSC Publishing,
[2012]
|
| Series | RSC drug discovery series ;
21. |
| Subjects | |
| Online Access | Full text |
| ISBN | 9781849734912 1849734917 9781621981435 1621981436 9781849733625 1849733627 |
| Physical Description | 1 online resource (xxvii, 365 pages) : illustrations |
Cover
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | kn-ocn789150271 | ||
| 003 | OCoLC | ||
| 005 | 20240717213016.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 120425t20122012enka ob 001 0 eng d | ||
| 040 | |a UKRSC |b eng |e rda |e pn |c UKRSC |d COO |d UIU |d MYG |d KNOVL |d YDXCP |d N$T |d ZCU |d OHS |d KNOVL |d OCLCF |d KNOVL |d NLGGC |d KNOVL |d MHW |d OCLCQ |d MMU |d E7B |d OCLCQ |d DEBSZ |d OCLCQ |d D6H |d AGLDB |d BUF |d OCLCQ |d OCLCO |d VTS |d RRP |d NLE |d UKMGB |d STF |d AU@ |d OCLCO |d OCLCQ |d OCLCO |d ERF |d OCLCQ |d OCLCA |d MM9 |d AJS |d OCLCQ |d OCLCA |d OCLCO |d OCL |d OCLCQ |d OCLCO |d OCLCQ |d OCLCL |d SXB | ||
| 020 | |a 9781849734912 |q (electronic bk.) | ||
| 020 | |a 1849734917 |q (electronic bk.) | ||
| 020 | |a 9781621981435 |q (electronic bk.) | ||
| 020 | |a 1621981436 |q (electronic bk.) | ||
| 020 | |a 9781849733625 |q (hardback) | ||
| 020 | |a 1849733627 |q (hardback) | ||
| 035 | |a (OCoLC)789150271 |z (OCoLC)785730758 |z (OCoLC)788647207 |z (OCoLC)810436453 |z (OCoLC)823728090 |z (OCoLC)843641057 | ||
| 245 | 0 | 0 | |a Designing multi-target drugs / |c editors, J. Richard Morphy and C. John Harris. |
| 264 | 1 | |a Cambridge, U.K. : |b RSC Publishing, |c [2012] | |
| 264 | 4 | |c ©2012 | |
| 300 | |a 1 online resource (xxvii, 365 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a RSC drug discovery series ; |v 21 | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Simple drugs do not cure complex diseases: the need for multi-targeted drugs -- Clinical need and rationale for multi-target drugs in psychiatry -- Drug molecules and biology: network and systems aspects -- Chemoinformatic approaches to target identification -- Designing multi-target drugs: in vitro panel screening, biological fingerprinting -- Phenotypic and in vivo screening: lead discovery and drug repurposing -- Target/s identification approaches: experimental biological approaches -- Historical strategies for lead generation -- In silico lead generation approaches in multi-target drug discovery -- The challenges of multi-target lead optimization -- Combination agents versus multi-targeted agents: pros and cons -- The discovery of lapatinib -- Identification and optimization of dual PI3K/mTOR inhibitors -- Discovery of HDAC-inhibiting multi-target inhibitors -- Targeting protein-protein interactions: dual inhibitors of Bcl-2 and Bcl-xL -- Discovery of the anti-psychotic drug, ziprasidone -- The rational design of triple reuptake inhibitors for the treatment of depression -- Discovery of multi-target agents for neurological diseases via ligand design -- Designing drugs with dual activity: novel dual angiotensin II and endothelin receptor antagonists -- Ethyl urea inhibitors of the bacterial type II topoisomerases DNA gyrase (GyrB) and topoisomerase IV (ParE). | |
| 506 | |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty | ||
| 520 | |a "Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs that are thought to derive their therapeutic benefit by virtue of interacting with multiple targets, the majority of these were discovered accidentally. Written by world renowned experts, this is the first book to gather together knowledge and experiences of the rational discovery of multi-target drugs. It describes the current state of the art, the achievements and the challenges of the field and importantly the lessons learned by researchers to date and their application to future MTDD."-- |c Provided by publisher. | ||
| 590 | |a Knovel |b Knovel (All titles) | ||
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 0 | |a Drug targeting. | |
| 650 | 0 | |a Polypharmacy. | |
| 655 | 7 | |a elektronické knihy |7 fd186907 |2 czenas | |
| 655 | 9 | |a electronic books |2 eczenas | |
| 700 | 1 | |a Morphy, Richard, |e editor. | |
| 700 | 1 | |a Harris, C. John, |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Designing multi-target drugs. |d Cambridge : Royal Society of Chemistry, 2012 |z 9781849733625 |w (OCoLC)779245878 |
| 830 | 0 | |a RSC drug discovery series ; |v 21. | |
| 856 | 4 | 0 | |u https://proxy.k.utb.cz/login?url=https://app.knovel.com/hotlink/toc/id:kpDMTD0003/designing-multi-target?kpromoter=marc |y Full text |